Mitochondrial fission – a drug target for cytoprotection or cytodestruction?

Rosdah, Ayeshah Augusta and Holien, Jessica K. and Delbridge, Lea M.D. and Dusting, Gregory J. and Lim, Shiang Y. (2016) Mitochondrial fission – a drug target for cytoprotection or cytodestruction? Pharmacology Research and Perspectives, 4 (3). pp. 1-19. ISSN e00235

PDF (Artikel jurnal) - Published Version
Download (1040Kb) | Preview


    Mitochondria are morphologically dynamic organelles constantly undergoing processes of fission and fusion that maintain integrity and bioenergetics of the organelle: these processes are vital for cell survival. Disruption in the balance of mitochondrial fusion and fission is thought to play a role in several pathological conditions including ischemic heart disease. Proteins involved in regulating the processes of mitochondrial fusion and fission are therefore potential targets for pharmacological therapies. Mdivi-1 is a small molecule inhibitor of the mitochondrial fission protein Drp1. Inhibiting mitochondrial fission with Mdivi-1 has proven cytoprotective benefits in several cell types involved in a wide array of cardiovascular injury models. On the other hand, Mdivi-1 can also exert antiproliferative and cytotoxic effects, particularly in hyperproliferative cells. In this review, we discuss these divergent effects of Mdivi-1 on cell survival, as well as the potential and limitations of Mdivi-1 as a therapeutic agent.

    Item Type: Article
    Uncontrolled Keywords: mitochondria, fission, drug target
    Subjects: R Medicine > RM Therapeutics. Pharmacology
    Divisions: Faculty of Medicine > Department of Medicine
    Depositing User: dr. Ayeshah Augusta Rosdah
    Date Deposited: 27 Apr 2017 15:10
    Last Modified: 27 Apr 2017 15:10

    Actions (login required)

    View Item